PsO Pipeline Update: Enrollment Complete in Phase 3 Program of Alumis’ Oral TYK2 Inhibitor May 29, 2025
Switching Biologics in Psoriasis: First Person Dosed in New Study of Anti-IL-17 Treatment-Resistant Patients May 29, 2025
Registration Now Open for Inaugural H&W Global Dermatology CME Conference in November 2025 May 28, 2025
Milestone Alert: More Than 300,000 Patients With Suspicious Lesions Have Been Assessed Using Nevisense May 27, 2025